The C5a receptor also known as complement component 5a receptor 1 (C5AR1) or CD88 (Cluster of Differentiation 88) is a G protein-coupled receptor for C5a. It functions as a complement receptor.[1] C5a receptor modulates inflammatory responses, obesity, development and cancers.[2][3][4]
↑Brennan FH, Gordon R, Lao HW, Biggins PJ, Taylor SM, Franklin RJ, Woodruff TM, Ruitenberg MJ (April 2015). "The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury". The Journal of Neuroscience. 35 (16): 6517–31. doi:10.1523/JNEUROSCI.5218-14.2015. PMID25904802.
↑Lim J, Iyer A, Suen JY, Seow V, Reid RC, Brown L, Fairlie DP (February 2013). "C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling". FASEB Journal. 27 (2): 822–31. doi:10.1096/fj.12-220582. PMID23118029.
↑Klos A, Wende E, Wareham KJ, Monk PN (January 2013). "International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors". Pharmacological Reviews. 65 (1): 500–43. doi:10.1124/pr.111.005223. PMID23383423.
↑Wong AK, Finch AM, Pierens GK, Craik DJ, Taylor SM, Fairlie DP (August 1998). "Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a". Journal of Medicinal Chemistry. 41 (18): 3417–25. doi:10.1021/jm9800651. PMID9719594.
↑Gong Y, Barbay JK, Buntinx M, Li J, Wauwe JV, Claes C, Lommen GV, Hornby PJ, He W (July 2008). "Design and optimization of aniline-substituted tetrahydroquinoline C5a receptor antagonists". Bioorganic & Medicinal Chemistry Letters. 18 (14): 3852–5. doi:10.1016/j.bmcl.2008.06.059. PMID18595693.
↑Sumichika H, Sakata K, Sato N, Takeshita S, Ishibuchi S, Nakamura M, Kamahori T, Ehara S, Itoh K, Ohtsuka T, Ohbora T, Mishina T, Komatsu H, Naka Y (December 2002). "Identification of a potent and orally active non-peptide C5a receptor antagonist". The Journal of Biological Chemistry. 277 (51): 49403–7. doi:10.1074/jbc.M209672200. PMID12384495.
Beil WJ, Schulz M, Wefelmeyer U (July 2000). "Mast cell granule composition and tissue location--a close correlation". Histology and Histopathology. 15 (3): 937–46. PMID10963136.
Yamamoto T (January 2007). "Roles of the ribosomal protein S19 dimer and the C5a receptor in pathophysiological functions of phagocytic leukocytes". Pathology International. 57 (1): 1–11. doi:10.1111/j.1440-1827.2007.02049.x. PMID17199736.
Bao L, Gerard NP, Eddy RL, Shows TB, Gerard C (June 1992). "Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19". Genomics. 13 (2): 437–40. doi:10.1016/0888-7543(92)90265-T. PMID1612600.
Gerard NP, Gerard C (February 1991). "The chemotactic receptor for human C5a anaphylatoxin". Nature. 349 (6310): 614–7. doi:10.1038/349614a0. PMID1847994.
Boulay F, Mery L, Tardif M, Brouchon L, Vignais P (March 1991). "Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells". Biochemistry. 30 (12): 2993–9. doi:10.1021/bi00226a002. PMID2007135.
Wahl SM, Allen JB, Gartner S, Orenstein JM, Popovic M, Chenoweth DE, Arthur LO, Farrar WL, Wahl LM (May 1989). "HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes". Journal of Immunology. 142 (10): 3553–9. PMID2541200.
Giannini E, Brouchon L, Boulay F (August 1995). "Identification of the major phosphorylation sites in human C5a anaphylatoxin receptor in vivo". The Journal of Biological Chemistry. 270 (32): 19166–72. doi:10.1074/jbc.270.32.19166. PMID7642584.
Buhl AM, Osawa S, Johnson GL (August 1995). "Mitogen-activated protein kinase activation requires two signal inputs from the human anaphylatoxin C5a receptor". The Journal of Biological Chemistry. 270 (34): 19828–32. doi:10.1074/jbc.270.34.19828. PMID7649993.
Wennogle LP, Conder L, Winter C, Braunwalder A, Vlattas S, Kramer R, Cioffi C, Hu SI (July 1994). "Stabilization of C5a receptor--G-protein interactions through ligand binding". Journal of Cellular Biochemistry. 55 (3): 380–8. doi:10.1002/jcb.240550316. PMID7962171.
Gerard NP, Bao L, Xiao-Ping H, Eddy RL, Shows TB, Gerard C (February 1993). "Human chemotaxis receptor genes cluster at 19q13.3-13.4. Characterization of the human C5a receptor gene". Biochemistry. 32 (5): 1243–50. doi:10.1021/bi00056a007. PMID8383526.
Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C, Zeng Z, Su K, Jurewicz AJ, Hertzberg RP, Bergsma DJ, Kumar C (August 1996). "Molecular cloning and characterization of the human anaphylatoxin C3a receptor". The Journal of Biological Chemistry. 271 (34): 20231–4. doi:10.1074/jbc.271.34.20231. PMID8702752.
Werfel T, Zwirner J, Oppermann M, Sieber A, Begemann G, Drommer W, Kapp A, Götze O (August 1996). "CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin". Journal of Immunology. 157 (4): 1729–35. PMID8759762.
Höpken UE, Lu B, Gerard NP, Gerard C (September 1996). "The C5a chemoattractant receptor mediates mucosal defence to infection". Nature. 383 (6595): 86–9. doi:10.1038/383086a0. PMID8779720.
Chen Z, Zhang X, Gonnella NC, Pellas TC, Boyar WC, Ni F (April 1998). "Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin". The Journal of Biological Chemistry. 273 (17): 10411–9. doi:10.1074/jbc.273.17.10411. PMID9553099.
Floreani AA, Heires AJ, Welniak LA, Miller-Lindholm A, Clark-Pierce L, Rennard SI, Morgan EL, Sanderson SD (May 1998). "Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke". Journal of Immunology. 160 (10): 5073–81. PMID9590258.
Ottonello L, Corcione A, Tortolina G, Airoldi I, Albesiano E, Favre A, D'Agostino R, Malavasi F, Pistoia V, Dallegri F (June 1999). "rC5a directs the in vitro migration of human memory and naive tonsillar B lymphocytes: implications for B cell trafficking in secondary lymphoid tissues". Journal of Immunology. 162 (11): 6510–7. PMID10352266.
Kohleisen B, Shumay E, Sutter G, Foerster R, Brack-Werner R, Nuesse M, Erfle V (December 1999). "Stable expression of HIV-1 Nef induces changes in growth properties and activation state of human astrocytes". AIDS. 13 (17): 2331–41. doi:10.1097/00002030-199912030-00004. PMID10597774.